Review for "Improved Glycemic Variability and Time in Range with Dapagliflozin versus Gliclazide Modified Release among Adults with Type 2 Diabetes Evaluated by Continuous Glucose Monitoring: A 12‐week Randomized Controlled Trial"

Mapping Intimacies ◽

10.1111/dom.13913/v1/review3 ◽

2019 ◽

Author(s):

Tasuku Terada

Keyword(s):

Type 2 Diabetes ◽

Randomized Controlled Trial ◽

Continuous Glucose Monitoring ◽

Controlled Trial ◽

Glucose Monitoring ◽

Glycemic Variability ◽

Modified Release ◽

Randomized Controlled ◽

Time In Range

Download Full-text

Decision letter for "Improved Glycemic Variability and Time in Range with Dapagliflozin versus Gliclazide Modified Release among Adults with Type 2 Diabetes Evaluated by Continuous Glucose Monitoring: A 12‐week Randomized Controlled Trial"

10.1111/dom.13913/v3/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Randomized Controlled Trial ◽

Continuous Glucose Monitoring ◽

Controlled Trial ◽

Glucose Monitoring ◽

Glycemic Variability ◽

Modified Release ◽

Randomized Controlled ◽

Time In Range

Download Full-text

Review for "Improved Glycemic Variability and Time in Range with Dapagliflozin versus Gliclazide Modified Release among Adults with Type 2 Diabetes Evaluated by Continuous Glucose Monitoring: A 12‐week Randomized Controlled Trial"

10.1111/dom.13913/v2/review3 ◽

2019 ◽

Author(s):

Tasuku Terada

Keyword(s):

Type 2 Diabetes ◽

Randomized Controlled Trial ◽

Continuous Glucose Monitoring ◽

Controlled Trial ◽

Glucose Monitoring ◽

Glycemic Variability ◽

Modified Release ◽

Randomized Controlled ◽

Time In Range

Download Full-text

Review for "Improved Glycemic Variability and Time in Range with Dapagliflozin versus Gliclazide Modified Release among Adults with Type 2 Diabetes Evaluated by Continuous Glucose Monitoring: A 12‐week Randomized Controlled Trial"

10.1111/dom.13913/v2/review1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Randomized Controlled Trial ◽

Continuous Glucose Monitoring ◽

Controlled Trial ◽

Glucose Monitoring ◽

Glycemic Variability ◽

Modified Release ◽

Randomized Controlled ◽

Time In Range

Download Full-text

Review for "Improved Glycemic Variability and Time in Range with Dapagliflozin versus Gliclazide Modified Release among Adults with Type 2 Diabetes Evaluated by Continuous Glucose Monitoring: A 12‐week Randomized Controlled Trial"

10.1111/dom.13913/v1/review1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Randomized Controlled Trial ◽

Continuous Glucose Monitoring ◽

Controlled Trial ◽

Glucose Monitoring ◽

Glycemic Variability ◽

Modified Release ◽

Randomized Controlled ◽

Time In Range

Download Full-text

Author response for "Improved Glycemic Variability and Time in Range with Dapagliflozin versus Gliclazide Modified Release among Adults with Type 2 Diabetes Evaluated by Continuous Glucose Monitoring: A 12‐week Randomized Controlled Trial"

10.1111/dom.13913/v2/response1 ◽

2019 ◽

Author(s):

Andre G. D. Vianna ◽

Claudio S. Lacerda ◽

Luciana M. Pechmann ◽

Michelle G. Polesel ◽

Emerson C. Marino ◽

...

Keyword(s):

Type 2 Diabetes ◽

Randomized Controlled Trial ◽

Continuous Glucose Monitoring ◽

Controlled Trial ◽

Glucose Monitoring ◽

Glycemic Variability ◽

Modified Release ◽

Randomized Controlled ◽

Time In Range

Download Full-text

Decision letter for "Improved Glycemic Variability and Time in Range with Dapagliflozin versus Gliclazide Modified Release among Adults with Type 2 Diabetes Evaluated by Continuous Glucose Monitoring: A 12‐week Randomized Controlled Trial"

10.1111/dom.13913/v1/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Randomized Controlled Trial ◽

Continuous Glucose Monitoring ◽

Controlled Trial ◽

Glucose Monitoring ◽

Glycemic Variability ◽

Modified Release ◽

Randomized Controlled ◽

Time In Range

Download Full-text

Review for "Improved Glycemic Variability and Time in Range with Dapagliflozin versus Gliclazide Modified Release among Adults with Type 2 Diabetes Evaluated by Continuous Glucose Monitoring: A 12‐week Randomized Controlled Trial"

10.1111/dom.13913/v3/review2 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Randomized Controlled Trial ◽

Continuous Glucose Monitoring ◽

Controlled Trial ◽

Glucose Monitoring ◽

Glycemic Variability ◽

Modified Release ◽

Randomized Controlled ◽

Time In Range

Download Full-text

Review for "Improved Glycemic Variability and Time in Range with Dapagliflozin versus Gliclazide Modified Release among Adults with Type 2 Diabetes Evaluated by Continuous Glucose Monitoring: A 12‐week Randomized Controlled Trial"

10.1111/dom.13913/v3/review1 ◽

2019 ◽

Author(s):

Tasuku Terada

Keyword(s):

Type 2 Diabetes ◽

Randomized Controlled Trial ◽

Continuous Glucose Monitoring ◽

Controlled Trial ◽

Glucose Monitoring ◽

Glycemic Variability ◽

Modified Release ◽

Randomized Controlled ◽

Time In Range

Download Full-text

Review for "Improved Glycemic Variability and Time in Range with Dapagliflozin versus Gliclazide Modified Release among Adults with Type 2 Diabetes Evaluated by Continuous Glucose Monitoring: A 12‐week Randomized Controlled Trial"

10.1111/dom.13913/v2/review2 ◽

2019 ◽

Author(s):

桂一鳥本

Keyword(s):

Type 2 Diabetes ◽

Randomized Controlled Trial ◽

Continuous Glucose Monitoring ◽

Controlled Trial ◽

Glucose Monitoring ◽

Glycemic Variability ◽

Modified Release ◽

Randomized Controlled ◽

Time In Range

Download Full-text

Decision letter for "Improved Glycemic Variability and Time in Range with Dapagliflozin versus Gliclazide Modified Release among Adults with Type 2 Diabetes Evaluated by Continuous Glucose Monitoring: A 12‐week Randomized Controlled Trial"

10.1111/dom.13913/v2/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Randomized Controlled Trial ◽

Continuous Glucose Monitoring ◽

Controlled Trial ◽

Glucose Monitoring ◽

Glycemic Variability ◽

Modified Release ◽

Randomized Controlled ◽

Time In Range

Download Full-text